FMC Corp. (NYSE: FMC) agreed to pay $345 million for Epax AS, a Norwegian supplier of Omega 3 fatty acids, as a means to grow the Philadelphia company’s nutrition and health offerings.

Oslo-based Epax, which will be folded into FMC’s specialty chemicals business, is co-owned by private equity firm Lindsay Goldberg and Norwegian biotechnology company Aker BioMarine ASA under the joint venture Trygg Pharma Group AS.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.